Neues Risiko für arzneimittelbedingte Leberschäden und Empfehlung zur Überwachung der Leberfunktion vor und während der Behandlung
← Back
AI-generated summary
Dear Healthcare Professional Letter: Ocrevus (ocrelizumab) – new risk of drug-induced liver injury
Original title: Rote-Hand-Brief: Ocrevus (Ocrelizumab)
New safety concern identified for ocrelizumab regarding drug-induced liver injury; liver function monitoring recommended before and during treatment.